(NASDAQ:CVRX), Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5% Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11% Fiscal 2026 revenue expected to be between $63 million and $67 million, representing growth of 11% to 18% Category I […]
— Study highlights importance of cancer driver biology in translating results from lab to patients — — Findings validate proprietary OncoSLX Platform(TM), a pharmacogenetic approach that captures the full spectrum of drug biology — — Continuing to advance lead asset LFB190, a BET inhibitor, targeting EP300 lossâ€'ofâ€'function cancers; expect to initiate Phase 1b/2a clinical trial
(NASDAQ:RKDA), DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.(R) (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 808,595 shares originally issued in December 2020, January
(NASDAQ:GERN), 2026 RYTELO(R) (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward building a sustainable hematology company FOSTER CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Geron Corporation
(NASDAQ:COGT), New Drug Application (NDA) for NonAdvSM submitted in December 2025, NDA submission for AdvSM on track for 1H 2026 NDA submission for GIST on track for April 2026; bezuclastinib has the potential to be the first new therapy for second-line GIST in over 20 years Clinical data presentations from all three pivotal trials, PEAK,
(NASDAQ:INAB), Repeat-doses of DeltEx(TM) Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to 13.0 months compared to only 6.6 months (+97%) in a control cohort treated with the standard-of-care (SOC) Stupp protocol Median overall survival (mOS) continues to climb, currently at 17.2+ months as of December 31, 2025, with several
(NASDAQ:SPAI), AVENTURA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) — Safe Pro Group Inc. (Nasdaq: SPAI) (“Safe Pro” or the “Company”), a developer of artificial intelligence (AI)-enabled defense and security solutions, announced today that its Florida based wholly owned ballistics protection unit, Safe-Pro USA LLC (Safe-Pro USA) will be exhibiting at the upcoming SHOT Show 2026
(NASDAQ:ERAS), Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation Initial Phase 1 monotherapy data for ERAS-0015 (potential best-in-class pan-RAS molecular glue) planned for H1 2026 and for ERAS-4001 (potential first-in-class pan-KRAS inhibitor) planned for
(NASDAQ:CABA), Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose IND amendment cleared to manufacture rese-cel with the automated, scalable Cellares platform based on multiple successful engineering runs; clinical manufacturing data expected in 1H26 to confirm GMP readiness, including
(NASDAQ:NCPL),(NASDAQ:NCPLW),(TSX-V:PWH), Signs PureWave Hydrogen as Initial Client BOSTON, MA, Jan. 12, 2026 (GLOBE NEWSWIRE) — Netcapital Inc. (NASDAQ: NCPL, NCPLW), a digital private capital markets ecosystem, today announced that it has engaged its first issuer of tokenized assets. As part of this initiative, Netcapital has commenced work with PureWave Hydrogen Corp. (TSX.V: PWH), a company